文献速递胰腺与胆道疾病消化道肿瘤与早癌

高危个体胰腺癌筛查(胰腺扫描研究):前瞻性多中心研究的检出率、危害与结局

Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes From a Prospective Multicenter Study.
PubMed 文献 · Am J Gastroenterol · 2023-05-04

这项前瞻性多中心研究纳入2020至2022年5个中心接受胰腺癌筛查的252例高危个体,采用内镜超声和/或磁共振胰胆管成像每年筛查,并每年用空腹血糖筛查新发糖尿病。高危病变检出率为0.8%(2例),筛查未发生不良事件,无患者接受低产出胰腺手术。

要点

  • 252例高危个体中高危病变检出2例(0.8%),为T2N1M0和T2N1M1期胰腺癌。
  • 低危病变占23.4%,中危病变占31.7%,几乎均为无担忧特征的 branch-duct IPMN。
  • 筛查未发生不良事件,无患者接受低产出胰腺手术。

核心结论

  • 胰腺癌筛查检出高危病变的频率低于既往报道,且未观察到筛查相关危害。

研究设计与样本

  • 前瞻性多中心研究,2020至2022年在5个中心纳入252例接受胰腺癌筛查的高危个体,平均年龄59.9岁,69%为女性,79.4%为白人。
  • 每年采用内镜超声和/或磁共振胰胆管成像筛查,并每年用空腹血糖筛查新发糖尿病(ClinicalTrials.gov:NCT05006131)。

主要发现

  • 低危病变(脂肪变或慢性胰腺炎样改变)占23.4%,中危病变(<2 cm的神经内分泌肿瘤或 branch-duct IPMN)占31.7%,几乎均为无担忧特征的 branch-duct IPMN。
  • 高危病变(高级别胰腺上皮内瘤变/异型增生、主胰管型IPMN、>2 cm的神经内分泌肿瘤或胰腺癌)见于2例(0.8%),分别诊断为T2N1M0和T2N1M1期胰腺癌。
  • 糖尿病前期占18.2%,新发糖尿病占1.7%;空腹血糖异常与胰腺病变无关联。
  • 筛查试验未发生不良事件,无患者接受低产出胰腺手术。

关键数值与推荐

  • 常见筛查指征包括BRCA1/2(36.9%)、家族性胰腺癌综合征亲属(31.7%)、共济失调毛细血管扩张突变(3.5%)、Lynch综合征(6.7%)、Peutz-Jeghers综合征(4.3%)和家族性非典型多发性黑色素瘤(3.5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Guidelines endorse pancreatic cancer screening in genetically susceptible individuals. We conducted a prospective, multicenter study to determine yield, harms, and outcomes of pancreatic cancer screening. METHODS: All high-risk individuals undergoing pancreatic cancer screening at 5 centers from 2020 to 2022 were prospectively enrolled. Pancreas findings were designated as low-risk (fatty or chronic pancreatitis-like changes), intermediate-risk (neuroendocrine tumor [NET] <2 cm or branch-duct intraductal papillary mucinous neoplasm [IPMN]), or high-risk lesions (high-grade pancreatic intraepithelial neoplasia/dysplasia, main-duct IPMN, NET >2 cm, or pancreatic cancer). Harms from screening included adverse events during screening or undergoing low-yield pancreatic surgery. Annual screening was performed using endoscopic ultrasound and or magnetic resonance cholangiopancreatography. Annual screening for new-onset diabetes using fasting blood sugar was also performed ( ClinicalTrials.gov : NCT05006131). RESULTS: During the study period, 252 patients underwent pancreatic cancer screening. Mean age was 59.9 years, 69% were female, and 79.4% were White. Common indications were BRCA 1/2 (36.9%), familial pancreatic cancer syndrome kindred (31.7%), ataxia telangiectasia mutated (3.5%), Lynch syndrome (6.7%), Peutz-Jeghers (4.3%), and familial atypical multiple mole melanoma (3.5%). Low-risk lesions were noted in 23.4% and intermediate-risk lesions in 31.7%, almost all of which were branch-duct IPMN without worrisome features. High-risk lesions were noted in 2 patients (0.8%), who were diagnosed with pancreas cancer at stages T2N1M0 and T2N1M1. Prediabetes was noted in 18.2% and new-onset diabetes in 1.7%. Abnormal fasting blood sugar was not associated with pancreatic lesions. There were no adverse events from screening tests, and no patient underwent low-yield pancreatic surgery. DISCUSSION: Pancreatic cancer screening detected high-risk lesions with lower frequency than previously reported. No harms from screening were noted.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shah I, Silva-Santisteban A, Germansky KA, et al. Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes From a Prospective Multicenter Study. Am J Gastroenterol. 2023. PMID: 37141538. doi:10.14309/ajg.0000000000002314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。